These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35163821)

  • 1. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
    Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
    Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soyasaponin A
    Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
    Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
    Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
    Li H; Xi Y; Xin X; Tian H; Hu Y
    Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
    Gay MD; Safronenka A; Cao H; Liu FH; Malchiodi ZX; Tucker RD; Kroemer A; Shivapurkar N; Smith JP
    Cancer Prev Res (Phila); 2021 Jan; 14(1):17-30. PubMed ID: 33115780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice.
    Li Q; Li M; Li F; Zhou W; Dang Y; Zhang L; Ji G
    J Ethnopharmacol; 2020 Aug; 258():112896. PubMed ID: 32325178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
    Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W
    Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvia-Nelumbinis naturalis extract protects mice against MCD diet-induced steatohepatitis via activation of colonic FXR-FGF15 pathway.
    Li C; Zhou W; Li M; Shu X; Zhang L; Ji G
    Biomed Pharmacother; 2021 Jul; 139():111587. PubMed ID: 33865013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hammerhead-type FXR agonists induce an enhancer RNA
    Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
    Elife; 2024 Apr; 13():. PubMed ID: 38619504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet.
    Kong B; Luyendyk JP; Tawfik O; Guo GL
    J Pharmacol Exp Ther; 2009 Jan; 328(1):116-22. PubMed ID: 18948497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis.
    Yang C; Wan M; Xu D; Pan D; Xia H; Yang L; Sun G
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
    Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
    J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
    Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
    Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.